publication date: Feb. 21, 2020

In Brief

Pamela Kunz named leader of GI Cancers Program at Yale

Pamela L. Kunz was named leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center, and director of GI Medical Oncology within the Section of Medical Oncology.

Kunz joins Yale from Stanford University School of Medicine, where she is director of the Stanford Neuroendocrine Tumor Program, leader of the Endocrine Research Group, and director of the Neuroendocrine Tumor Fellowship.

“Beyond her record of accomplishment in GI Oncology, Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine tumors and is advancing the field through clinical trials and translational science that are defining the next generation of therapies for patients with this difficult diagnosis,” Charles Fuchs, director of Yale Cancer Center and physician-in-chief at Smilow Cancer Hospital, said in a statement.

Kunz serves on the board of directors for the North American Neuroendocrine Tumor Society and is vice chair of the NCI Neuroendocrine Tumor Task Force.

Kunz will start her new position in July.


Jennifer Carlson named chair of NCCN’s newly formed Government Affairs committee

Jennifer Carlson, associate vice president for external relations & advocacy at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, was named inaugural chair of the National Comprehensive Cancer Network’s Government Affairs Committee.

The appointment became effective in late 2019.

As chair of the Governmental Affairs Committee, Carlson will lead a forum to fulfill NCCN’s policy priorities through the development and advancement of state and federal policy and advocacy activities. 

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.